Sam Smith (@scolbysmith)
Activity by Sam Smith
ROCHESTER, Minn. â€” Dosing obese teens with vitamin D shows no benefits for their heart health or diabetes risk, and could have the unintended consequences of increasing cholesterol and fat-storing triglycerides. These are the latest findings in a series of Mayo Clinic studies in childhood obesity.
Seema Kumar, M.D., a pediatric endocrinologist in the Mayo Clinic Childrenâ€™s Center, has been studying the effects of vitamin D supplementation in children for 10 years, through four clinical trials and six published studies. To date, Dr. Kumarâ€™s team has found limited benefit from vitamin D supplements in adolescents. The latest study, Effect of Vitamin D3 Treatment on Endothelial Function in Obese Adolescents, appears online in Pediatric Obesity.
â€śAfter three months of having vitamin D boosted into the normal range with supplements, these teenagers showed no changes in body weight, body mass index, waistline, blood pressure or blood flow,â€ť says Dr. Kumar. â€śWeâ€™re not saying the links between vitamin D deficiencyÂ and chronic diseases donâ€™t exist for childrenâ€”we just havenâ€™t found anyÂ yet.â€ť
I am so sorry to hear about your husband. I will reach out to Dr. Ho's research coordinator and team. You should also feel free to do so. Even discuss the study and press release with your treating oncologist; he or she may know whether application of this technology is appropriate for your husband's care. Please let me know how I can help further.
Samuel Smith | Public Affairs Specialist | Mayo Clinic | External Relations - Research Communications | 507-266-0607 office | 815-535-1902 cell | firstname.lastname@example.org
SCOTTSDALE, Ariz. â€” An international research team led by Mayo Clinic oncologists has found a new way to identify and possibly stop the progression of many late-stage cancers, including bladder, blood, bone,Â brain,Â lung and kidney.
The precision medicine study appears onlineÂ inÂ OncogeneÂ and focuses on kidney cancer and its metastases. Recent studies of the sameÂ epigenomicÂ fingerprint in other cancers suggest a common pathway that could help improve the diagnosis and treatment of advanced disease across a wide variety of cancer types.
â€śIf you think of late-stage cancer as a runaway car, most of our drugs take a shot at a tire here and there, but sometimes they miss and often they canâ€™t stop it entirely,â€ť saysÂ Thai Ho, M.D., Ph.D., a Mayo Clinic oncologist and lead author of the study. â€śWe believe we have identified a mechanism that seizes the cancerâ€™s biological engine and could potentially stop it in its tracks.â€ť
The new approach zeroes in on an epigenomic fingerprint in metastatic disease, in which the body often misinterprets a healthy genetic blueprint, producing toxic cells that run afoul of the bodyâ€™s normal functions.
MEDIA CONTACT: Sam Smith, Mayo Clinic Public Affairs, 507-284-5005, email@example.com.
ROCHESTER, Minn. â€” A. Keith Stewart, M.B., Ch.B., has been appointed medical director of the Mayo Clinic Center for Individualized Medicine. Dr. Stewart is a consultant in the Division of Hematology-Oncology, Department of Medicine.
â€śI am honored to have this opportunity,â€ť says Dr. Stewart. â€śWe will build on the excellent work of the center to date, with a renewed focus on helping our clinicians access genomics based diagnostics and therapeutics on a routine basis to improve patient care. The integrated complex care delivered at Mayo Clinic provides a unique ability to lead in the development of precision medicine advances with global impact.â€ť
Dr. Stewartâ€™s own research and clinical interest is in translational genomics in multiple myeloma, including both basic and clinical research to identify novel targets for therapy in multiple myeloma. A diversity of public and private institutions currently support this work: the National Cancer Institute, Multiple Myeloma Research Foundation, and Leukemia and Lymphoma Society, as well as numerous partnerships with the pharmaceutical industry for clinical trials.
ROCHESTER, Minn.Â â€” Sen. Amy Klobuchar (D-Minn.) affirmed her commitment to medicalÂ innovationÂ andÂ precision medicine today during a tour of the Mayo Clinic Biorepositories'Â new state-of-the-artÂ space inÂ northwest Rochester.
"President Obama made precision medicine a common term ... andÂ I'm delightedÂ to be here to see first-hand the workÂ that has been going here at Mayo Clinic for quite some time," Klobuchar said. "We need to continue to support medical research and fund the NIHâ€”we increasingly are facing international competition."
Obama announced the NIH's $270 millionÂ Precision Medicine Initiative on January 20 during this year'sÂ State of the Union Address, thrusting the relatively obscure medical term into the national spotlight and launching a national dialogue about medical innovation and genomics in clinical care.
Klobuchar called the initiative "imperative" to the future of health care in the United States and aÂ keyÂ componentÂ of the local and state economies.
"America has always been a leader (in health innovation)," Klobuchar said. "We want those dollars, those jobs, right here in Rochester, in the Twin Cities." [...]
ROCHESTER, Minn. â€” Sen. Amy Klobuchar, D-Minn., will tour the Mayo Clinic Biobank and discuss the Precision Medicine Initiative with leadership from both the Mayo Clinic Center for Individualized Medicine and Mayo Medical Laboratories. Journalists are welcome to accompany Sen. Klobuchar and join the informational tour of Mayo Clinicâ€™s multi-million-dollar investment in precision medicine. Mayo Clinic leadership will also be available for interviews and background discussions.
WHAT: Walking tour of the Mayo Clinic Biobank and the Biorepositories Program of the Mayo Clinic Center for Individualized Medicine. Photo opportunities and opportunities to discuss the Precision Medicine Initiative with Sen. Klobuchar and Mayo Clinic leadership.
WHERE:Â Biorepositories BuildingÂ of Mayo Clinic, 2915 Valleyhigh Drive NW, Rochester, MN 55901. Entrance is behind the building.
WHEN: Friday, February 20, from 11:15 to 11:40 a.m.
NOTE: Members of the media should RSVP to 507-284-5005.
MEDIA CONTACT: Sam Smith, 507-284-5005, firstname.lastname@example.org.
Mayo ClinicÂ is excited about the national focus on individualized medicine and what the future holds. More than half ($130 million) of the total $215 million budget request, put forth by President Obama's Precision Medicine Initiative, is for a national biobanking initiative that draws on existing collections across the country. Mayo Clinic has among the countryâ€™s largest collections through the Mayo Clinic Biobank and the Biorepositories Program.
Mayo Clinic and the Mayo ClinicÂ Center for Individualized Medicine have made a significant commitment to building a scalableÂ biorepository infrastructure, which includes multipleÂ specimen processing laboratories and centralized storage.
One of these collections is the Mayo Clinic Biobank, a collection of blood samples and health information donated by Mayo Clinic patients.Â The Biobank collects samples and health information from patients and other volunteers, regardless of health history.Â The Biobank was established at Mayo Clinic's campus in Rochester, Minn., and recruitment began in April 2009. Since then, the Biobank has expanded to Mayo Clinic's campuses in Jacksonville, Fla. and Scottsdale, Ariz., in addition to the Mayo Clinic Health System. The Biobank aims to enroll 50,000 Mayo Clinic patients by 2016 to support a wide array of health-related research studies at Mayo Clinic and other institutions.
Steve Thibodeau, David F. and Margaret T. GrohneÂ Director, Biorepositories Program facts about the Mayo Clinic Biobank.
Journalists: Soundbites with Dr. ThibodeauÂ and b-roll of the Mayo Clinic BiobankÂ are available in the downloads.
MEDIA CONTACT: Sam Smith, Mayo Clinic Public Affairs, 507-284-5005,Â email@example.com
Rochester, Minn. â€” A new breast imaging technique pioneered at Mayo Clinic nearly quadruples detection rates of invasive breast cancers in women with dense breast tissue, according to the results of a major study published this week in the American Journal of Roentgenology.
Molecular Breast Imaging (MBI) is a supplemental imaging technology designed to find tumors that would otherwise be obscured by surrounding dense breast tissue on a mammogram. Tumors and dense breast tissue can both appear white on a mammogram, making tumors indistinguishable from background tissue in women with dense breasts. About half of all screening-aged women have dense breast tissue, according to Deborah Rhodes, M.D., a Mayo Clinic Breast Clinic physician and the senior author of this study.
MBI increased the detection rate of invasive breast cancers by more than 360 percent when used in addition to regular screening mammography, according to the study. MBI uses small, semiconductor-based gamma cameras to image the breast following injection of a radiotracer that tumors absorb avidly. Unlike conventional breast imaging techniques, such as mammography and ultrasound, MBI exploits the different behavior of tumors relative to background tissue, producing a functional image of the breast that can detect tumors not seen on mammography.
The study, conducted at Mayo Clinic, included 1,585 women with heterogeneously or extremely dense breasts who underwent an MBI exam at the time of their screening mammogram.